Gastroesophageal Reflux Disease Management

Medication Guidance

The American Gastroenterological Association recommends avoiding NSAIDs in patients with GERD whenever possible, and if required, administering them with a proton pump inhibitor (PPI) for gastroprotection 1
For patients requiring NSAIDs, the European Society for Clinical Gastrointestinal Endoscopy suggests using the lowest effective dose of NSAID in combination with a PPI, especially for low-risk GERD patients 2
The American College of Gastroenterology recommends using a COX-2 selective inhibitor plus a PPI as a second choice, and an NSAID plus a PPI as a third choice for high-risk GERD patients 2
PPIs, such as omeprazole or esomeprazole, are recommended by the American College of Cardiology as the most effective drugs for protecting the stomach against aspirin-induced gastric injury 3, 4
The American College of Gastroenterology recommends using a PPI for gastric protection in patients on chronic NSAIDs, especially in those with advanced age (≥65 years), as it increases the risk of gastrointestinal complications approximately 2-3.5 fold 2

PPIs reduce gastric acid secretion for up to 36 hours, providing more consistent acid suppression than H2-receptor antagonists (H2RAs) 4
PPIs like pantoprazole are particularly important when administering NSAIDs to patients with age ≥65 years, history of peptic ulcer disease or GI bleeding, concurrent use of anticoagulants, concurrent use of corticosteroids, or concurrent use of multiple NSAIDs or aspirin 2, 5
The American Heart Association recommends omeprazole 20mg daily or esomeprazole 20mg daily as first-line treatment 3, 4

The combination of aspirin plus esomeprazole showed significantly lower recurrent bleeding rates (0.7%) compared to clopidogrel alone (8.6%) in patients with a history of ulcer bleeding taking low-dose aspirin 3
Omeprazole heals and prevents ulcers more effectively than ranitidine in patients requiring continuous NSAID treatment 3
PPIs provide greater reduction in upper GI bleeding risk (OR: 0.04) compared to H2RAs (OR: 0.43) in patients taking aspirin and clopidogrel 4
Enteric-coated aspirin does not reduce GI bleeding risk, with similar relative risks of upper GI bleeding for plain, enteric-coated, and buffered aspirin at 325mg daily doses (2.6, 2.7, and 3.1, respectively) 3
Lower aspirin doses (75mg) reduce but do not eliminate bleeding risk compared to higher doses (300mg) 3
Even low-dose aspirin increases GI bleeding risk 2-3 fold 3

The risk of serious gastrointestinal complications is significantly higher in patients with a history of previous peptic ulcer or ulcer complications, advanced age (>65 years), concomitant use of multiple NSAIDs, low-dose aspirin, corticosteroids, or anticoagulants, and Helicobacter pylori infection, as reported by the American Gastroenterological Association 6 and the European Society of Gastrointestinal Endoscopy 7

The following risk stratification is recommended:

Risk Level	Management Strategy
Low-risk	Use the least ulcerogenic NSAID at the lowest effective dose, with short-term use when possible [8]
Moderate-risk	Use an NSAID plus PPI or misoprostol, or a COX-2 inhibitor alone [8]
High-risk	Use a COX-2 inhibitor plus PPI for concomitant aspirin, a COX-2 inhibitor plus misoprostol for concomitant warfarin, or a COX-2 inhibitor for concomitant steroids [8]
Very high-risk	Avoid NSAIDs completely if possible, or use a COX-2 inhibitor plus PPI if an NSAID is necessary [8]

Regular monitoring of GI symptoms, renal function, and blood pressure is essential 6
PPI therapy should be continued for the entire duration of NSAID treatment, as recommended by the American College of Gastroenterology 6
Routine H. pylori testing is not recommended for all patients starting NSAID therapy, but test and treat H. pylori in patients with a history of ulcer or ulcer complications, according to the American Gastroenterological Association 6
The American Gastroenterological Association recommends de-prescribing PPIs when there is no clear ongoing indication, due to concerns with long-term PPI use in geriatric patients, including increased risk of Clostridium difficile infection, potential for hypomagnesemia, risk of bone loss and fractures, medication burden and cost, and potential drug interactions 9
Rebound acid hypersecretion may occur when PPIs are discontinued, potentially worsening gastritis symptoms, as noted by the American Gastroenterological Association 9

The following ranking of oral NSAIDs by relative analgesic potency can be used:
NSAID Relative Analgesic Potency
Diclofenac High
Indomethacin High
Meloxicam Medium
Naproxen Medium
Ibuprofen Low
Aspirin Low
Naproxen has the most favorable cardiovascular profile, whereas COX-2 selective inhibitors have increased cardiovascular risk, according to the American Heart Association 10